Avillion, Pfizer partner on Phase III trial for Bosulif

Avillion LLP (London, U.K.) partnered with Pfizer Inc. (NYSE:PFE) to conduct an international Phase III trial evaluating Pfizer's Bosulif bosutinib as first-line treatment for patients with chronic Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). Avillion will fund and conduct the trial. If Bosulif is approved for the indication, Avillion would be eligible for undisclosed milestones. Pfizer retains rights to Bosulif, which is already approved in the U.S. and EU to treat Ph+ CML in previously treated patients. ...